Ultragenyx (RARE) rises this week as investors weigh catalysts

Ultragenyx Pharmaceutical (RARE) is rallying as investors process FDA approval of Fayuvi and multiple higher Wall Street price targets, while awaiting additional catalysts including shipments of its newly approved therapies and Wilson disease trial results.